Journey Medical Corp (DERM) stock
DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% below fair value
$4.33−0.06 (-1.37%)
Close on Nov 13, 2026Market cap $122.21MP/E –Yield –
Journey Medical EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Journey Medical's EPS for the twelve months ending Sep 30, 2026 was -$0.19. For fiscal 2025 it was -$0.47. The highest annual figure on record is $0.49 in fiscal 2020.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.47 | – |
| FY2024 | Dec 31, 2024 | -$0.72 | – |
| FY2023 | Dec 31, 2023 | -$0.21 | – |
| FY2022 | Dec 31, 2022 | -$1.69 | – |
| FY2021 | Dec 31, 2021 | -$4.32 | -981.6% |
| FY2020 | Dec 31, 2020 | $0.49 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.05 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.01 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.08 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.05 | -171.4% |
| Q3 FY2025 | Sep 30, 2025 | -$0.09 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.16 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.18 | – |
| Q4 FY2024 | Dec 31, 2024 | $0.07 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.12 | -115.0% |
| Q2 FY2024 | Jun 30, 2024 | -$0.17 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.53 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.11 | – |
| Q3 FY2023 | Sep 30, 2023 | $0.80 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.60 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.57 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.43 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.08 | -500.0% |
| Q4 FY2021 | Dec 31, 2021 | -$1.64 | -813.0% |
| Q3 FY2021 | Sep 30, 2021 | -$1.16 | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.30 | – |
| Q1 FY2021 | Mar 31, 2021 | $0.02 | – |
| Q4 FY2020 | Dec 31, 2020 | $0.23 | – |
| Q3 FY2020 | Sep 30, 2020 | $0.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?